Prophylactic effect of HOE/BAY 946, a new anti-viral agent, on SIV and simian AIDS.

Important note: Information in this article was accurate in 1991. The state of the art may have changed since the publication date.

Prophylactic effect of HOE/BAY 946, a new anti-viral agent, on SIV and simian AIDS.

Symp Nonhum Primate Models AIDS. 1990 Nov 28-30;8:77 (abstract no. 61). Unique Identifier : AIDSLINE PRIM8/900061
Cheung AT; Lerche NW; Schrinner EJ; Schlumberger HD; Young LJ; Yee JL; Department of Medical Pathology and California Primate Research; Center, University of California, Davis, California, USA

Abstract: HOE/BAY 946, a disodium salt of xylanpoly-hydrogen sulphate, shows significant in vitro inhibitory activities against the reverse transcriptases of retroviruses, including SIV, HIV, AMV, and FLV. The pharmacokinetic profile of this compound is known and it is currently used for other indications with no significant adverse effects on human patients. The ID50-value for HOE/BAY 946 is determined to be at 2 mu g/ml. SIV infection is completely inhibited at 25 mu g/ml in cultures of HUT78 cells and peripheral blood mononuclear cells. Effectiveness of HOE/BAY 946 on SIV infection is confirmed by absence of syncytium formation and baseline scores in antigen capture and reverse transcriptase assays. HOE/BAY 946 exhibits a remarkable in vivo delaying effect on SIV antibody seroconversion in rhesus monkeys inoculated with SIV. For rhesus monkeys (n=6) inoculated with an effective inoculum of SIV and immediately treated with HOE/BAY 946, an average delay of 5 weeks in SIV antibody sero-conversion (via Western blot studies) results. The maximal delay obtained is 10 weeks in our controlled study. Sero-conversion for SIV HOE/BAY 946 treated rhesus monkeys (n=6) occurred in 4-12 weeks (an average delay of 5 weeks). This sero-conversion delay indicates a significant prophylactic effect of HOE/BAY 946 on SIV infection and simian AIDS. In a parallel in vitro study, HIV infection is completely inhibited by HOE/BAY 946 (at 25 mu g/ml) in cultures of HUT78 cells and peripheral blood mononuclear cells. During treatment with HOE/BAY 946, absence of syncytium formation is confirmed and baseline scores in antigen capture and reverse transcriptase assays are obtained. In view of the similarities, further efficacy study on the prophylactic effect of HOE/BAY 946 on SIV and simian AIDS may bear unique significance in the search for a medication to control HIV and AIDS.

Keywords: Animal Antibodies, Viral/IMMUNOLOGY Antigens, Viral/IMMUNOLOGY Antiviral Agents/*PHARMACOKINETICS Cells, Cultured Human Leukocytes, Mononuclear/MICROBIOLOGY Macaca mulatta Polysaccharides/*PHARMACOKINETICS RNA-Directed DNA Polymerase/ANTAGONISTS & INHIB Simian Acquired Immunodeficiency Syndrome/EPIDEMIOLOGY/PREVENTION & CONTROL SIV/*DRUG EFFECTS/ENZYMOLOGY/IMMUNOLOGY ABSTRACT
910730
M9170933

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1991. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1991. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .